tiprankstipranks
Lexicon receives CRL for Zynquista
PremiumThe FlyLexicon receives CRL for Zynquista
2M ago
Lexicon price target lowered to $1.20 from $4 at Citi
Premium
The Fly
Lexicon price target lowered to $1.20 from $4 at Citi
3M ago
Lexicon announces completion of enrollment in Phase 2B PROGRESS study
Premium
The Fly
Lexicon announces completion of enrollment in Phase 2B PROGRESS study
3M ago
Lexicon Pharmaceuticals Reports Q3 2024 Financial Results
PremiumCompany AnnouncementsLexicon Pharmaceuticals Reports Q3 2024 Financial Results
3M ago
Lexicon reports Q3 EPS (18c), consensus (16c)
Premium
The Fly
Lexicon reports Q3 EPS (18c), consensus (16c)
3M ago
Lexicon Pharmaceuticals options imply 14.8% move in share price post-earnings
Premium
The Fly
Lexicon Pharmaceuticals options imply 14.8% move in share price post-earnings
3M ago
FDA panel votes 11-3 that Lexicon’s Zynquista benefits do not outweigh risks
PremiumThe FlyFDA panel votes 11-3 that Lexicon’s Zynquista benefits do not outweigh risks
4M ago
FDA Endocrinologic and Metabolic Drugs Advisory Committee to hold a meeting
Premium
The Fly
FDA Endocrinologic and Metabolic Drugs Advisory Committee to hold a meeting
4M ago
Lexicon announces new analysis of Phase 3 SCORED trial
Premium
The Fly
Lexicon announces new analysis of Phase 3 SCORED trial
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100